Dilated cardiomyopathy laboratory findings

Jump to navigation Jump to search

Dilated cardiomyopathy Microchapters


Patient Information


Historical Perspective




Differentiating Dilated cardiomyopathy from other Diseases

Epidemiology and Demographics

Risk Factors


Natural History, Complications and Prognosis


Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings



Echocardiography and Ultrasound

CT scan


Other Imaging Findings

Other Diagnostic Studies


Medical Therapy


Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Dilated cardiomyopathy laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of Dilated cardiomyopathy laboratory findings

All Images
Echo & Ultrasound
CT Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Dilated cardiomyopathy laboratory findings

CDC on Dilated cardiomyopathy laboratory findings

Dilated cardiomyopathy laboratory findings in the news

Blogs on Dilated cardiomyopathy laboratory findings

Directions to Hospitals Treating Dilated cardiomyopathy

Risk calculators and risk factors for Dilated cardiomyopathy laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdelrahman Ibrahim Abushouk, MD[2]


The majority of dilated cardiomyopathy laboratory workup is targeted towards detecting the cause (such as thyroid function tests, toxicology screening, and genetic counselling) or assessing the cardiac complications of the condition. Other biomarkers that are under investigation include serum uric acid, Ca-125, soluble ST2, and Growth and differentiation factor-15.

Laboratory Findings

Most of the laboratory workup for dilated cardiomyopathy is usually targeted towards detecting the cause.[1]

Other laboratory investigations may target the severity of the condition or its effect on the cardiac function.

Other biomarkers currently under investigation include:


  1. Japp AG, Gulati A, Cook SA, Cowie MR, Prasad SK (2016). "The Diagnosis and Evaluation of Dilated Cardiomyopathy". J Am Coll Cardiol. 67 (25): 2996–3010. doi:10.1016/j.jacc.2016.03.590. PMID 27339497.
  2. Karaca O, Guler GB, Guler E, Gunes HM, Alizade E, Agus HZ; et al. (2012). "Serum carbohydrate antigen 125 levels in nonischemic dilated cardiomyopathy: a useful biomarker for prognosis and functional mitral regurgitation". Congest Heart Fail. 18 (3): 144–50. doi:10.1111/j.1751-7133.2011.00260.x. PMID 22587744.
  3. Bielecka-Dabrowa A, Wierzbicka M, Dabrowa M, Goch A (2008). "New methods in laboratory diagnostics of dilated cardiomyopathy". Cardiol J. 15 (4): 388–95. PMID 18698552.
  4. Lichtenauer M, Jirak P, Wernly B, Paar V, Rohm I, Jung C; et al. (2017). "A comparative analysis of novel cardiovascular biomarkers in patients with chronic heart failure". Eur J Intern Med. 44: 31–38. doi:10.1016/j.ejim.2017.05.027. PMID 28579310.
  5. Nair N, Gongora E (2018). "Correlations of GDF-15 with sST2, MMPs, and worsening functional capacity in idiopathic dilated cardiomyopathy: Can we gain new insights into the pathophysiology?". J Circ Biomark. 7: 1849454417751735. doi:10.1177/1849454417751735. PMC 5777561. PMID 29375722.
  6. Jackson CE, Haig C, Welsh P, Dalzell JR, Tsorlalis IK, McConnachie A; et al. (2015). "Combined Free Light Chains Are Novel Predictors of Prognosis in Heart Failure". JACC Heart Fail. 3 (8): 618–25. doi:10.1016/j.jchf.2015.03.014. PMID 26251088.

Template:WH Template:WS